ARMP News & Events

The company recognized grant revenue of $1.1M for the three months ended December 31, 2025 as compared to $1.2M in the comparable period in 2024, which represents MTEC's share of the costs incurred for the company's AP-SA02 program for the treatment of Staphylococcus aureus bacteremia.

Armata Pharmaceuticals announced that it will delay the announcement of its financial results for its fourth quarter and full-year ended December 31, 2025. The Company requires additional time to complete its financial reporting and anticipates filing its Annual Report on Form 10-K on or before March 31, 2026, the due date.

Armata Pharmaceuticals announced that the U.S. FDA has granted AP-SA02, the company's Staphylococcus aureus multi-phage product candidate, for intravenous use as a Qualified Infectious Disease Product for adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus or methicillin resistant S. aureus. The company plans to advance AP-SA02 into a Phase 3 superiority study in complicated S. aureus bacteremia, anticipated to initiate in the second half of 2026.